Biogen (NASDAQ:BIIB) Price Target Raised to $185.00

Biogen (NASDAQ:BIIB) had its price objective boosted by JPMorgan Chase & Co. from $175.00 to $185.00 in a note issued to investors on Thursday,MarketScreener reports. The firm currently has a “neutral” rating on the biotechnology company’s stock. JPMorgan Chase & Co.‘s target price indicates a potential downside of 2.30% from the company’s previous close.

Other analysts have also issued research reports about the company. Mizuho lifted their target price on Biogen from $207.00 to $236.00 and gave the stock an “outperform” rating in a report on Tuesday, February 10th. TD Cowen lifted their price objective on Biogen from $175.00 to $215.00 and gave the stock a “buy” rating in a report on Monday, February 9th. UBS Group raised Biogen from a “neutral” rating to a “buy” rating and lifted their price objective for the stock from $185.00 to $225.00 in a report on Wednesday. Wedbush lifted their price objective on Biogen from $187.00 to $191.00 and gave the stock a “neutral” rating in a report on Wednesday, April 1st. Finally, Sanford C. Bernstein reaffirmed a “market perform” rating on shares of Biogen in a report on Monday, February 9th. Fourteen equities research analysts have rated the stock with a Buy rating, thirteen have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and an average price target of $211.31.

Biogen Stock Down 0.4%

Shares of Biogen stock traded down $0.71 on Thursday, reaching $189.36. The company’s stock had a trading volume of 101,612 shares, compared to its average volume of 1,317,769. The company has a market capitalization of $27.79 billion, a price-to-earnings ratio of 21.50, a P/E/G ratio of 2.48 and a beta of 0.16. The firm’s fifty day simple moving average is $185.53 and its two-hundred day simple moving average is $174.73. Biogen has a 52 week low of $115.25 and a 52 week high of $202.41. The company has a quick ratio of 2.03, a current ratio of 2.68 and a debt-to-equity ratio of 0.34.

Biogen (NASDAQ:BIIB) last posted its earnings results on Friday, February 6th. The biotechnology company reported $1.99 EPS for the quarter, topping analysts’ consensus estimates of $1.61 by $0.38. The business had revenue of $2.28 billion during the quarter, compared to analyst estimates of $2.21 billion. Biogen had a return on equity of 12.64% and a net margin of 13.07%.The company’s quarterly revenue was down 7.2% compared to the same quarter last year. During the same quarter last year, the company earned $3.44 EPS. Biogen has set its FY 2026 guidance at 15.250-16.250 EPS. Equities analysts anticipate that Biogen will post 15.82 earnings per share for the current year.

Insiders Place Their Bets

In related news, insider Priya Singhal sold 2,660 shares of Biogen stock in a transaction on Monday, February 9th. The stock was sold at an average price of $199.83, for a total transaction of $531,547.80. Following the transaction, the insider directly owned 8,043 shares in the company, valued at approximately $1,607,232.69. The trade was a 24.85% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 0.18% of the company’s stock.

Hedge Funds Weigh In On Biogen

Institutional investors and hedge funds have recently bought and sold shares of the stock. Reflection Asset Management purchased a new position in Biogen during the fourth quarter valued at $25,000. WPG Advisers LLC lifted its position in Biogen by 417.9% during the fourth quarter. WPG Advisers LLC now owns 145 shares of the biotechnology company’s stock valued at $26,000 after purchasing an additional 117 shares in the last quarter. Accredited Wealth Management LLC lifted its position in shares of Biogen by 1,233.3% in the third quarter. Accredited Wealth Management LLC now owns 200 shares of the biotechnology company’s stock valued at $28,000 after acquiring an additional 185 shares in the last quarter. First Horizon Corp purchased a new position in shares of Biogen in the fourth quarter valued at about $30,000. Finally, WFA of San Diego LLC purchased a new position in shares of Biogen in the second quarter valued at about $32,000. 87.93% of the stock is currently owned by hedge funds and other institutional investors.

Key Headlines Impacting Biogen

Here are the key news stories impacting Biogen this week:

• Positive Sentiment: UBS upgraded BIIB to Buy and raised its price target to $225, citing a string of near?term pipeline and commercial catalysts that could lift the stock into 2027 — this is a major buy?side endorsement likely driving investor optimism. UBS Upgrades Biogen to Buy With a $225 Target: Are the Next 12 Months a Pipeline Catalyst Parade?
• Positive Sentiment: Biogen secured Greater China rights to felzartamab (immune?disease asset), giving it broader commercial control as global Phase III programs progress — a deal that supports upside to future revenues in Asia. BIIB Inks Deal to Acquire Rights to Felzartamab in China, Stock Up
• Positive Sentiment: Jim Cramer said he’s “reopening the file” on Biogen on Mad Money after recent analyst coverage, which can spur retail interest and momentum trading. Jim Cramer Says “I Got to Reopen the File on Biogen”
• Positive Sentiment: Wolfe Research raised its FY?2027 EPS view (higher long?term earnings projection), signaling some sell?side confidence in Biogen’s multi?year earnings power even as near?term estimates shift.
• Neutral Sentiment: TipRanks/coverage pieces reiterate the UBS view that Biogen’s late?stage pipeline, the Apellis acquisition and valuation discount could support sizable upside — this echoes the UBS thesis but is largely confirmatory. Biogen: Underappreciated Late?Stage Pipeline, Apellis Acquisition, and Valuation Discount Support 25–50% Upside
• Neutral Sentiment: Coverage of a separate commercial/partnering deal (TJ Biopharma) attracted attention and volume — supportive for narrative but not yet material to financials. Biogen Zooms on Deal with TJ Biopharma
• Negative Sentiment: HSBC reiterated a Reduce rating with a $150 target and published below?consensus multi?year EPS scenarios — a clear bearish analyst voice that can cap upside and raise downside risk.
• Negative Sentiment: Wolfe Research trimmed its Q1?2026 EPS estimate (lower near?term quarter projection), which increases odds of a tougher near?term earnings print.
• Negative Sentiment: Several previews and opinion pieces warn of weaker near?term earnings or valuation concerns ahead of results (Zacks preview; “3 Reasons to Avoid” article), which can temper momentum heading into the report. Earnings Preview: Biogen Inc. (BIIB) Q1 Earnings Expected to Decline 3 Reasons to Avoid BIIB and 1 Stock to Buy Instead

Biogen Company Profile

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.